Invitae (Invitae) Momentum Rank : 0 (As of May. 11, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Invitae Momentum Rank?

Invitae has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Invitae Momentum Rank Related Terms

Thank you for viewing the detailed overview of Invitae's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Invitae (Invitae) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

NVTA:Mexico IV8:Germany

Address

1400 16th Street, San Francisco, CA, USA, 94103

Website

https://www.invitae.com

Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.

Executives

Ana J. Schrank	officer: Chief Financial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley	officer: Chief Commercial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey	officer: See Remarks	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons	officer: See remarks	2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum	officer: Chief Medical Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida	officer: General Counsel	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner	officer: Chief Accounting Officer	2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen	officer: Chief Financial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight	officer: Chief Operating Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne	director	1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George	director, officer: CEO	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer	officer: Chief Financial Officer	1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland	officer: Chief Commercial Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse	director	3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers	director, other: President, Oncology	C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301